See the DrugPatentWatch profile for Lantus
Lantus Solostar is a brand name for a long-acting insulin, specifically insulin glargine [1]. It is used to manage blood sugar levels in adults and children who have type 1 or type 2 diabetes [2]. The medication is delivered via a pre-filled disposable pen device [3].
What is Lantus Solostar and how does it work?
Lantus Solostar is a human insulin analog designed to provide a basal (long-acting) source of insulin [1][4]. Insulin glargine works by mimicking the action of naturally produced insulin, lowering glucose levels by helping glucose move from the blood into tissues and by stopping the liver from producing glucose [5]. Its long-acting profile means it is typically taken once a day to maintain a steady background level of insulin [4].
When does Lantus Solostar patent exclusivity expire?
Information on the specific patent expiration dates for Lantus Solostar can be found on specialized patent tracking websites. DrugPatentWatch.com provides comprehensive data on drug patents, including expiration timelines [6]. This data is crucial for understanding when generic versions of the drug may become available.
How does Lantus Solostar compare to other insulins?
Lantus Solostar belongs to a class of long-acting insulins. Unlike rapid-acting insulins, which are taken with meals, or intermediate-acting insulins, which typically have a peak effect, Lantus Solostar is designed for a more consistent, peakless action over a longer period, usually 24 hours [4]. This distinction is important for achieving stable blood glucose control between meals and overnight.
What are the potential risks and side effects of Lantus Solostar?
The most common side effect associated with Lantus Solostar, like other insulins, is hypoglycemia (low blood sugar) [2][7]. Symptoms of hypoglycemia can include dizziness, sweating, hunger, tremors, and confusion. Other potential side effects include injection site reactions, lipodystrophy (changes in fat tissue at the injection site), and allergic reactions [7].
Can generic versions of Lantus Solostar be made?
The availability of generic versions of Lantus Solostar is dependent on patent expirations and regulatory approvals [6]. Once patents expire and regulatory bodies deem a generic bioequivalent, it can be approved and marketed. These generic versions, often referred to as biosimilars in the context of biologics like insulin, aim to offer a more affordable treatment option [8].
What are the costs associated with Lantus Solostar?
The cost of Lantus Solostar can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location [9]. As a branded biologic medication, it is generally more expensive than older, small-molecule drugs. The introduction of biosimilar or generic alternatives typically leads to price reductions in the market [8].
Who manufactures Lantus Solostar?
Lantus Solostar was originally developed and is manufactured by Sanofi [1]. Sanofi is a global pharmaceutical company.
What clinical data supports the use of Lantus Solostar?
Clinical trials for Lantus Solostar have demonstrated its efficacy and safety in managing blood glucose levels in individuals with diabetes [5]. These studies typically compare it against placebo or other existing insulin therapies to establish its therapeutic profile and benefit in various patient populations.
What are patient concerns regarding Lantus Solostar?
Patient concerns often revolve around the convenience of the pen device, the effectiveness in controlling blood sugar, and managing potential side effects like hypoglycemia [7]. Cost and access to the medication, especially with changing insurance plans or the availability of alternatives, are also common patient considerations.
Are there alternative treatments for long-acting insulin therapy?
Yes, there are other long-acting insulin analogs available, as well as other types of insulin that can be used for basal coverage [4][8]. The choice of insulin therapy depends on individual patient needs, lifestyle, and the guidance of a healthcare professional.
---
Cited Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugs.com/lantus-solostar.html
3. https://www.webmd.com/drugs/2/201003/lantus-solostar-injection/details
4. https://www.diabetes.co.uk/insulin/long-acting-insulin.html
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791425/
6. https://www.drugpatentwatch.com/blog/understanding-drug-patent-expiration-dates
7. https://www.goodrx.com/lantus-solostar
8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808096/
9. https://www.singlecare.com/prescription/lantus-solostar